Publication
Pseudoprogression During Enfortumab Vedotin Plus Pembrolizumab Therapy in Muscle-Invasive Bladder Cancer Achieving Pathological Complete Response: A Case Report.
Yosuke Nakanishi, Yohei Kawashima, Masanao Shinohara, Kazuhisa Hagiwara, Kohei Inui, Kazue Ogawa, Daiji Fujimori, Shingo Moriyama, Hanako Oba, Sato Satoshi
- Source
- PubMed
- Retrieved
- Sep 29, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-PUBMED-20260929-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
INTRODUCTION: Enfortumab vedotin plus pembrolizumab has emerged as a standard first-line therapy for advanced urothelial carcinoma (UC). However, pseudoprogression during this combination remains poorly characterized. CASE PRESENTATION: A 71-year-old man with muscle-invasive bladder cancer and…
Read on PubMedLinked entities
Linked entities (1)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Candidate 1
- cancerMalignant Bladder Neoplasmdictionary0.60
Curated evidence
Evidence citing this paper (0)
Data not yet available